Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial)

M. Valgimigli, P. Tricoci, Z. Huang, PE. Aylward, PW. Armstrong, F. Van de Werf, S. Leonardi, HD. White, P. Widimsky, RA. Harrington, A. Cequier, E. Chen, Y. Lokhnygina, L. Wallentin, J. Strony, KW. Mahaffey, DJ. Moliterno,

. 2014 ; 114 (5) : 665-73.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15007953
E-zdroje Online Plný text

NLK ProQuest Central od 2012-08-15 do Před 2 měsíci
Medline Complete (EBSCOhost) od 2012-09-01 do 2015-07-15
Nursing & Allied Health Database (ProQuest) od 2012-08-15 do Před 2 měsíci
Health & Medicine (ProQuest) od 2012-08-15 do Před 2 měsíci

Odkazy

PubMed 25129064
DOI 10.1016/j.amjcard.2014.05.054
Knihovny.cz E-zdroje

The therapeutic potential of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (PCI) is unknown. This prespecified analysis of a postrandomization subgroup evaluated the effects of vorapaxar compared with placebo among Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) participants undergoing PCI, focusing on the implanted stent type (drug-eluting stent [DES] vs bare-metal stent [BMS]). Among 12,944 recruited patients, 7,479 (57.8%) underwent PCI during index hospitalization, and 3,060 (40.9%) of those patients received exclusively BMS, whereas 4,015 (53.7%) received DES. The median (twenty-fifth, seventy-fifth percentiles) duration of thienopyridine therapy was 133 days (47, 246) with BMS and 221 days (88, 341) with DES. At 2 years among patients undergoing PCI, the primary (cardiovascular death, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization) and secondary (cardiovascular death, myocardial infarction, or stroke) end points did not differ between vorapaxar and placebo groups, which was consistent with the treatment effect observed in the overall study population (p value for interaction = 0.540). However, the treatment effect trended greater (p value for interaction = 0.069) and the risk for bleeding in patients taking vorapaxar versus placebo appeared attenuated in BMS-only recipients. After adjustment for confounders, the interaction was no longer significant (p value = 0.301). The covariate that mostly explained the stent-type-by-treatment interaction was the duration of clopidogrel therapy. In conclusion, among patients with PCI, the effect of vorapaxar is consistent with the overall TRACER results. Patients who received a BMS underwent shorter courses of clopidogrel therapy and displayed trends toward greater ischemic benefit from vorapaxar and lesser bleeding risk, compared with patients who received a DES.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15007953
003      
CZ-PrNML
005      
20211027154521.0
007      
ta
008      
150306s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.amjcard.2014.05.054 $2 doi
035    __
$a (PubMed)25129064
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Valgimigli, Marco $u Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands. Electronic address: m.valgimigli@erasmusmc.nl.
245    10
$a Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial) / $c M. Valgimigli, P. Tricoci, Z. Huang, PE. Aylward, PW. Armstrong, F. Van de Werf, S. Leonardi, HD. White, P. Widimsky, RA. Harrington, A. Cequier, E. Chen, Y. Lokhnygina, L. Wallentin, J. Strony, KW. Mahaffey, DJ. Moliterno,
520    9_
$a The therapeutic potential of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (PCI) is unknown. This prespecified analysis of a postrandomization subgroup evaluated the effects of vorapaxar compared with placebo among Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) participants undergoing PCI, focusing on the implanted stent type (drug-eluting stent [DES] vs bare-metal stent [BMS]). Among 12,944 recruited patients, 7,479 (57.8%) underwent PCI during index hospitalization, and 3,060 (40.9%) of those patients received exclusively BMS, whereas 4,015 (53.7%) received DES. The median (twenty-fifth, seventy-fifth percentiles) duration of thienopyridine therapy was 133 days (47, 246) with BMS and 221 days (88, 341) with DES. At 2 years among patients undergoing PCI, the primary (cardiovascular death, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization) and secondary (cardiovascular death, myocardial infarction, or stroke) end points did not differ between vorapaxar and placebo groups, which was consistent with the treatment effect observed in the overall study population (p value for interaction = 0.540). However, the treatment effect trended greater (p value for interaction = 0.069) and the risk for bleeding in patients taking vorapaxar versus placebo appeared attenuated in BMS-only recipients. After adjustment for confounders, the interaction was no longer significant (p value = 0.301). The covariate that mostly explained the stent-type-by-treatment interaction was the duration of clopidogrel therapy. In conclusion, among patients with PCI, the effect of vorapaxar is consistent with the overall TRACER results. Patients who received a BMS underwent shorter courses of clopidogrel therapy and displayed trends toward greater ischemic benefit from vorapaxar and lesser bleeding risk, compared with patients who received a DES.
650    _2
$a akutní koronární syndrom $x farmakoterapie $x patofyziologie $x chirurgie $7 D054058
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a dvojitá slepá metoda $7 D004311
650    12
$a stenty uvolňující léky $7 D054855
650    12
$a elektrokardiografie $7 D004562
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a injekce intravenózní $7 D007275
650    _2
$a laktony $x aplikace a dávkování $7 D007783
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a koronární angioplastika $x metody $7 D062645
650    _2
$a pooperační komplikace $x epidemiologie $7 D011183
650    _2
$a prospektivní studie $7 D011446
650    _2
$a pyridiny $x aplikace a dávkování $7 D011725
650    _2
$a receptory trombinu $x antagonisté a inhibitory $7 D018179
650    _2
$a míra přežití $x trendy $7 D015996
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Austrálie $x epidemiologie $7 D001315
651    _2
$a Evropa $x epidemiologie $7 D005060
651    _2
$a Spojené státy americké $x epidemiologie $7 D014481
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Tricoci, Pierluigi $u Duke Clinical Research Institute, Durham, North Carolina.
700    1_
$a Huang, Zhen $u Duke Clinical Research Institute, Durham, North Carolina.
700    1_
$a Aylward, Philip E $u Flinders University and Medical Centre, Bedford Park, Adelaide, Australia. $7 gn_A_00010589
700    1_
$a Armstrong, Paul W $u Division of Cardiology, University of Alberta, Edmonton, Canada. $7 gn_A_00008631
700    1_
$a Van de Werf, Frans $u Department of Cardiology, University of Leuven, Leuven, Belgium.
700    1_
$a Leonardi, Sergio $u Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
700    1_
$a White, Harvey D $u Green Lane Cardiovascular Service, Auckland, New Zealand.
700    1_
$a Widimsky, Petr $u University Hospital Kralovske Vinohrady, Charles University, Prague, Czech Republic.
700    1_
$a Harrington, Robert A $u Department of Medicine, Stanford University, Stanford, California.
700    1_
$a Cequier, Angel $u Hospital Universitari de Bellvitge, Universitat de Barcelona, Barcelona, Spain.
700    1_
$a Chen, Edmond $u Bayer HealthCare Pharmaceuticals Inc., Whippany, New Jersey.
700    1_
$a Lokhnygina, Yuliya $u Duke Clinical Research Institute, Durham, North Carolina.
700    1_
$a Wallentin, Lars $u Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala, Sweden.
700    1_
$a Strony, John $u Merck & Co., Whitehouse Station, New Jersey.
700    1_
$a Mahaffey, Kenneth W $u Department of Medicine, Stanford University, Stanford, California.
700    1_
$a Moliterno, David J. $u Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, Kentucky. $7 xx0265372
773    0_
$w MED00000236 $t The American journal of cardiology $x 1879-1913 $g Roč. 114, č. 5 (2014), s. 665-73
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25129064 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20211027154528 $b ABA008
999    __
$a ok $b bmc $g 1065226 $s 890753
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 114 $c 5 $d 665-73 $i 1879-1913 $m The American journal of cardiology $n Am J Cardiol $x MED00000236
LZP    __
$a Pubmed-20150306

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace